NCT06675565View on ClinicalTrials.gov

A Study to Evaluate ALN-AGT01 RVR in Adult Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

November 5, 2024

Primary Completion Date

September 8, 2025

Study Completion Date

September 8, 2025

Conditions
Healthy Volunteers
Interventions
DRUG

ALN-AGT01 RVR

ALN-AGT01 RVR will be administered subcutaneously (SC)

DRUG

Placebo

Placebo will be administered SC

Trial Locations (1)

Unknown

Clinical Trial Site, Montreal

Sponsors
All Listed Sponsors
lead

Alnylam Pharmaceuticals

INDUSTRY